Cartesian Therapeutics Inc (RNAC)
34.40
+2.96
(+9.41%)
USD |
NASDAQ |
May 31, 16:00
34.47
+0.07
(+0.20%)
After-Hours: 20:00
Cartesian Therapeutics Research and Development Expense (Quarterly): 9.738M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.738M |
| December 31, 2023 | 22.43M |
| September 30, 2023 | 13.00M |
| June 30, 2023 | 17.78M |
| March 31, 2023 | 18.62M |
| December 31, 2022 | 18.97M |
| September 30, 2022 | 16.54M |
| June 30, 2022 | 19.18M |
| March 31, 2022 | 17.69M |
| December 31, 2021 | 20.32M |
| September 30, 2021 | 20.95M |
| June 30, 2021 | 14.46M |
| March 31, 2021 | 13.00M |
| December 31, 2020 | 15.09M |
| September 30, 2020 | 13.96M |
| June 30, 2020 | 10.73M |
| March 31, 2020 | 14.72M |
| December 31, 2019 | 15.15M |
| September 30, 2019 | 8.104M |
| Date | Value |
|---|---|
| June 30, 2019 | 12.13M |
| March 31, 2019 | 7.353M |
| December 31, 2018 | 10.26M |
| September 30, 2018 | 11.88M |
| June 30, 2018 | 14.41M |
| March 31, 2018 | 11.14M |
| December 31, 2017 | 13.62M |
| September 30, 2017 | 9.504M |
| June 30, 2017 | 10.99M |
| March 31, 2017 | 11.04M |
| December 31, 2016 | 11.03M |
| September 30, 2016 | 6.021M |
| June 30, 2016 | 6.00M |
| March 31, 2016 | 6.648M |
| December 31, 2015 | 7.211M |
| September 30, 2015 | 5.483M |
| June 30, 2015 | 5.314M |
| March 31, 2015 | 4.972M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.104M
Minimum
Sep 2019
22.43M
Maximum
Dec 2023
15.63M
Average
15.12M
Median
Research and Development Expense (Quarterly) Benchmarks
| Marinus Pharmaceuticals Inc | 24.12M |
| Adial Pharmaceuticals Inc | 0.4543M |
| Poseida Therapeutics Inc | 42.92M |
| Viracta Therapeutics Inc | 9.956M |
| Biomea Fusion Inc | 33.78M |